Vertex claims success on its non-opioid pain drug, pushing candidate into pivotal trials
Vertex may soon have three irons in the fire in its bid to repeat the scientific and financial success of its blockbuster cystic fibrosis medicines.
The company on Thursday released positive results from a pair of Phase II trials for its non-opioid program, announcing that the experimental pill significantly reduced patients’ pain compared to placebo in two post-operative trials. One trial looked at patients who had just received a bunionectomy, the other in patients who received abdominoplasty — the medical term for a “tummy tuck.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.